Kairos Pharma, Ltd. (KAPA)Healthcare | Biotechnology | Los Angeles, United States | NYSE American
0.61 USD
+0.00
(0.016%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 0.62 +0.00 (0.556%) ⇧ (April 17, 2026, 7:55 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 3:31 p.m. EDT
KAPA is currently in a highly volatile and downward trend, with a recent price drop and negative fundamentals. The stock has shown no signs of momentum, and the recent news does not indicate strong positive catalysts. The short-term forecasting model predicts a further decline, which makes it a risky short-term trade. Long-term investors should be cautious due to the lack of sustainable growth and negative earnings. Additionally, there are no dividends to consider, making it unsuitable for dividend-focused investors. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.327434 |
| MSTL | 0.332282 |
| AutoETS | 0.346659 |
| AutoARIMA | 0.347280 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 38% |
| H-stat | 1.67 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 3.04 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 13,095,090 |
| Forward P/E | -1.12 |
| Website | https://kairospharma.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.32894737 |
| Address1 | 2,355 Westwood Boulevard |
| Address2 | Suite 139 |
| All Time High | 4.0 |
| All Time Low | 0.4 |
| Ask | 0.611 |
| Ask Size | 300 |
| Average Daily Volume10 Day | 63,840 |
| Average Daily Volume3 Month | 504,267 |
| Average Volume | 504,267 |
| Average Volume10Days | 63,840 |
| Bid | 0.6052 |
| Bid Size | 2,000 |
| Book Value | 0.305 |
| City | Los Angeles |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.6116 |
| Current Ratio | 27.07 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 0.6213 |
| Day Low | 0.6001 |
| Display Name | Kairos Pharma |
| Ebitda | -5,412,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.59 |
| Enterprise Value | 8,604,089 |
| Eps Current Year | -0.38 |
| Eps Forward | -0.545 |
| Eps Trailing Twelve Months | -0.3 |
| Esg Populated | 0 |
| Exchange | ASE |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.6001 |
| Fifty Day Average Change | 0.011500001 |
| Fifty Day Average Change Percent | 0.019163474 |
| Fifty Two Week Change Percent | -32.894737 |
| Fifty Two Week High | 2.11 |
| Fifty Two Week High Change | -1.4984 |
| Fifty Two Week High Change Percent | -0.7101422 |
| Fifty Two Week Low | 0.4 |
| Fifty Two Week Low Change | 0.21159998 |
| Fifty Two Week Low Change Percent | 0.5289999 |
| Fifty Two Week Range | 0.4 - 2.11 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,726,493,400,000 |
| Float Shares | 12,419,780 |
| Forward Eps | -0.545 |
| Forward P E | -1.1222018 |
| Free Cashflow | -1,632,500 |
| Full Exchange Name | NYSE American |
| Full Time Employees | 1 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.39863998 |
| Held Percent Institutions | 0.0813 |
| Implied Shares Outstanding | 21,411,199 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The company develops KROS 101, an orally available glucocorticoid-induced tumor necrosis factor receptor (GITR) ligand small-molecule antagonist to deplete regulatory T cells (Tregs) and activate effector T cells to augment the antitumor immune response for the treatment of patients with cancer, and a systemic immune modulator to address immunosuppressive activity of solid cancers; KROS 102, a GITR antagonist to increase the inhibitory regulatory Tregs functions; KROS 201 that activates the T cells using dendritic cells for the treatment of patients with glioblastoma; KROS 301, a tumor-targeting small molecule and checkpoint inhibitor with mechanisms of action resulting from blocking intranuclear localization of RelA, a key component of the NF-KB pathway, as well as targets tumor cells in RelA/p65 biomarker positive solid tumors; and KROS 401, a tumor microenvironment immune modulator and cyclic peptide inhibitor of IL-4 and IL-13 reversing tumor associated macrophage inhibition, and blocks the IL4/IL13 cytokine immune receptors for triple negative breast cancer. It also develops ENV 105, an antibody therapeutic for the prostate cancer patients resistant to androgen-targeted therapy, which is in Phase 2 clinical trial; and ENV 205, an antibody fragment that targets mitochondrial DNA. The company was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. Kairos Pharma, Ltd. was incorporated in 2013 and is based in Los Angeles, California. |
| Market | us_market |
| Market Cap | 13,095,090 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_1832548029 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -5,447,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 13,095,088 |
| Number Of Analyst Opinions | 3 |
| Open | 0.6277 |
| Operating Cashflow | -3,441,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 310 948 2356 |
| Post Market Change | 0.0034000278 |
| Post Market Change Percent | 0.55592346 |
| Post Market Price | 0.615 |
| Post Market Time | 1,776,470,101 |
| Previous Close | 0.6115 |
| Price Eps Current Year | -1.6094737 |
| Price Hint | 4 |
| Price To Book | 2.0052457 |
| Profit Margins | 0.0 |
| Quick Ratio | 22.568 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.000099957 |
| Regular Market Change Percent | 0.0163462 |
| Regular Market Day High | 0.6213 |
| Regular Market Day Low | 0.6001 |
| Regular Market Day Range | 0.6001 - 0.6213 |
| Regular Market Open | 0.6277 |
| Regular Market Previous Close | 0.6115 |
| Regular Market Price | 0.6116 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 50,983 |
| Return On Assets | -0.56589 |
| Return On Equity | -0.97994006 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 21,411,198 |
| Shares Percent Shares Out | 0.011 |
| Shares Short | 236,224 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 1,274,209 |
| Short Name | Kairos Pharma, Ltd. |
| Short Percent Of Float | 0.0162 |
| Short Ratio | 1.53 |
| Source Interval | 15 |
| State | CA |
| Symbol | KAPA |
| Target High Price | 12.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 8.33333 |
| Target Median Price | 9.0 |
| Total Cash | 4,491,000 |
| Total Cash Per Share | 0.21 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.3 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 0.90159 |
| Two Hundred Day Average Change | -0.28999 |
| Two Hundred Day Average Change Percent | -0.32164288 |
| Type Disp | Equity |
| Volume | 50,983 |
| Website | https://kairospharma.com |
| Zip | 90,064 |